Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (1): 36-40.doi: 10.6040/j.issn.1671-7554.0.2018.1316

Previous Articles    

Significance of 99mTc-PSMA SPECT/CT guided salvage lymph node dissection for prostate cancer patients with biochemical recurrence

SU Hengchuan1, ZHU Yao1, DAI Bo1, LIU Chang2, HU Silong2, YE Dingwei1   

  1. 1. Department of Urology, Shanghai Cancer Center of Fudan University, Shanghai Medical College, Fudan University, Shanghai 200032, China;
    2. Department of Nuclear Medicine, Shanghai Cancer Center of Fudan University, Shanghai 200032, China
  • Published:2022-09-27

PDF (PC)

25

Abstract: Objective To improve the value of salvage lymph node dissection for patients treated with radical prostatectomy(RP)with biochemical recurrence. Methods The clinical data of 3 typical cases treated with 99mTc-prostate-specific membrane antigen(PSMA)single photon emission computed tomography(SPECT)/CT guided salvage lymph node dissection during 2015 and 2017 were retrospectively analyzed. Results In case 1, the prostate specific antigen(PSA)control was not satisfactory after RP. PSMA SPECT/CT showed suspicious lymph node metastases near the left iliac blood vessels. After extended pelvic lymphadenectomy, the PSA level decreased to 0.2 ng/mL for 8 months and then increased again. In case 2, the PSA level increased to 22 ng/mL after RP. PSMA SPECT/CT showed suspicious retroperitoneal lymph node metastases. After retroperitoneal salvage lymph node dissection, the PSA level decreased to 10 ng/mL in 3 months and then bounced back. In case 3, after radical radiation, the PSA level gradually decreased and 山 东 大 学 学 报 (医 学 版)57卷1期 -宿恒川,等.PSMA SPECT/CT检查引导下的挽救性淋巴结清扫术在生化复发前列腺癌患者治疗中的价值 \=-then increased to 4 ng/mL. PSMA SPECT/CT showed suspicious lymph node metastases near the right iliac blood vessels. After salvage pelvic lymph node dissection plus radiation, the PSA level decreased to less than 0.2 ng/mL for 14 months and then increased. Conclusion For prostate cancer patients with biochemical recurrence, low PSA level and isolated nodal recurrence after RP, PSMA SPECT/CT guided salvage lymph node dissection can alleviate tumor burden and benefit the patients.

Key words: Prostate-specific membrane antigen, Prostate cancer, Metastatic lesions, Salvage lymph node dissection

CLC Number: 

  • R737.25
[1] Zhu Y, Wang HK, Qu YY, et al. Prostate cancer in East Asia: evolving trend over the last decade[J]. Asian J Androl, 2015, 17(1): 48-57.
[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30.
[3] Pagliarulo V. Androgen deprivation therapy for prostate cancer[J]. Adv Exp Med Biol, 2018, 1096: 1-30. doi:10.1007/978-3-319-99286-0_1.
[4] Crawford ED, Heidenreich A, Lawrentschuk N, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations[J]. Prostate Cancer Prostatic Dis, 2018. doi: 10.1038/s41391-018-0079-0.
[5] Maurer T, Robu S, Schottelius M, et al. 99mTechnetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer[J]. Eur Urol, 2018. pii: S0302-2838(18)30189-1. doi: 10.1016/j.eururo.2018.03.013.
[6] Ploussard G, Gandaglia G, Borgmann H, et al. Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review[J]. Eur Urol, 2018. pii: S0302-2838(18)30836-4. doi: 10.1016/j.eururo.2018.10.041.
[7] Rauscher I, Horn T, Eiber M, et al. Novel technology of molecular radio-guidance for lymph node dissection in recurrent prostate cancer by PSMA-ligands[J]. World J Urol, 2018, 36(4): 603-608.
[8] Bandini M, Fossati N, Briganti A. Salvage surgery for nodal recurrent prostate cancer[J]. Curr Opin Urol, 2017, 27(6): 604-611.
[9] Siriwardana A, Thompson J, van Leeuwen PJ, et al. Initial multicentre experience of 68gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited[J]. BJU Int, 2017, 120(5): 673-681.
[10] Montorsi F, Gandaglia G, Fossati N, et al. Robot-assisted salvage lymph node dissection for clinically recurrent prostate cancer[J]. Eur Urol, 2017, 72(3): 432-438.
[11] Rigatti P, Suardi N, Briganti A, et al. Pelvic/Retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by[11C] Choline Positron Emission Tomography/Computed Tomography[J]. Eur Urol, 2011, 60(5): 935-943.
[12] Osmonov DK, Aksenov AV, Trick D, et al. Cancer-specific and overall survival in patients with recurrent prostate cancer who underwent salvage extended pelvic lymph node dissection[J]. BMC Urol, 2016, 16(1): 56. doi:10.1186/s12894-016-0173-3.
[13] Tilki D, Mandel P, Seeliger F, et al. Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy[J]. J Urol, 2015, 193(2): 484-490.
[14] Suardi N, Gandaglia G, Gallina A, et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years[J]. Eur Urol, 2015, 67(2): 299-309.
[15] Herlemann A, Kretschmer A, Buchner A, et al. Salvage lymph node dissection after 68Ga-PSMA or 18F-FEC PET/ CT for nodal recurrence in prostate cancer patients[J]. Oncotarget, 2017, 8(48): 84180-84192.
[16] Passoni NM, Suardi N, Abdollah F, et al. Utility of[11C] choline PET/CT in guiding lesion targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series[J]. Urol Oncol, 2014, 32(1): 38. e9-16. doi:10.1016/j.urolonc.2013.03.006.
[17] Oderda M, Joniau S, Palazzetti A, et al. Is 11C-choline positron emission tomography/ computed tomography accurate to detect nodal relapses of prostate cancer after biochemical recurrence? a multicentric study based on pathologic confirmation from salvage lymphadenectomy[J]. Eur Urol Focus, 2018, 4(2): 288-293.
[18] Goldstein J, Even-Sapir E, Ben-Haim S, et al. Does choline PET/CT change the management of prostate cancer patients with biochemical failure?[J]. Am J Clin Oncol, 2017, 40(3): 256-259.
[19] Leiblich A, Stevens D, Sooriakumaran P. The utility of molecular imaging in prostate cancer[J]. Curr Urol Rep, 2016, 17(3): 26. doi: 10.1007/s11934-015-0573-z.
[20] Herlemann A, Wenter V, Kretschmer A, et al. 68Ga-PSMA positron emission tomography/ computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer[J]. Eur Urol, 2016, 70(4): 553-557.
[21] Rai BP, Baum RP, Patel A, et al. The role of positron emission tomography with(68)gallium(Ga)-labeled prostate-specific membrane antigen(PSMA)in the management of patients with organ-confined and locally advanced prostate cancer prior to radical treatment and after radical prostatectomy[J]. Urology, 2016, 95:11-15. doi:10.1016/j.urology.2015.12.048.
[22] Su HC, Zhu Y, Ling GW, et al. Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse[J]. Asian J Androl, 2017, 19(3): 267-271.
[23] Su HC, Zhu Y, Hu SL, et al. The value of 99mTc-PSMA SPECT/CT-guided surgery for identifying and locating lymph node metastasis in prostate cancer patients[J]. Ann Surg Oncol, 2018. doi: 10.1245/s10434-018-6805-y.
[24] Rauscher I, Düwel C, Wirtz M, et al. Value of 111 In-prostate-specific membrane antigen(PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up[J]. BJU Int, 2017, 120(1): 40-47.
[1] XU Zhen, DIAO Tongxiang, ZANG Zhenjie, SHAO Dingchang, ZHANG Qi, SUN Dingqi, FU Qiang. Value of isoform［-2］proprostate-specific antigen and its derivatives in the diagnosis of prostate cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(6): 51-56.
[2] SUN Haoyu, JIANG Xin, CHEN Shouzhen, QU Sifeng, SHI Benkang. Multiparametric magnetic resonance imaging combined with prostate health index in the diagnosis of prostate cancer in 142 patients within PSA grey zone [J]. Journal of Shandong University (Health Sciences), 2022, 60(6): 46-50.
[3] Benkang SHI,Shouzhen CHEN,Sifeng QU,Yong WANG,Lei LIU. Research progress and clinical characteristics of clinical rapidly progressing prostate cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 110-116.
[4] XU Bing, LI Yong, LIU Ming, LIU Yonghui. Silencing PRRX1 gene expression enhances the sensitivity of prostate cancer resistant cell line PC-3/DTX to docetaxel [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 103-110.
[5] SUN Dingqi, FU Qiang, ZHANG Hui, LIU Shuai, DIAO Tongxiang, CAO Qingwei, ZHANG Keqin. Clinical value of targeted multiparameter MRI and transrectal ultrasonography fusion prostate biopsy for the detection of PI-RADS≥3 prostate cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(4): 108-113.
[6] LÜ Jiaju, HU Jialin, DING Sentai. Advances in focal therapy for prostate cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 1-5.
[7] ZHOU Fangjian, HUANG Hua, LI Yonghong. Focal cryoablation for prostate cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 6-10.
[8] ZHU Gang, ZHANG Kai. Chinese prostate cancer screening: current situation and challenges [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 11-15.
[9] HAN Bangmin, JING Yifeng. Clinical management of oligometastatic prostate cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 26-29.
[10] YAO Xudong. Strategy and efficacy of surgical treatment in locally advanced prostate cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 21-25.
[11] WANG Haitao. Development of precision medicine in the treatment of castration-resistant prostate cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 30-35.
[12] MAO Shaowei, LU Guoliang, LI Liang, XIA Qinghua. Valproic acid augments the anti-tumor potential of metformin in PC-3 cells [J]. Journal of Shandong University (Health Sciences), 2018, 56(3): 48-53.
[13] DONG Wei, XING Naidong, LÜ Jiaju, LIU Shuai, SUN Liang, CAO Qingwei, DONG Yuhao, LIU Zhao, DING Sentai. The therapeutic efficacy of a potent KSP inhibitor S(MeO)TLC against docetaxel-resistant prostate cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 23-30.
[14] ZHAI Hongyun, ZHANG Denglu, WANG Guangjie, KONG Feng, CHENG Guanghui, ZHAO Shengtian. Effects of factors secreted by mouse embryonic stem cells on prostate cancer cells in vitro [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(9): 8-12.
[15] DING Huan1, SUN Ying1, LI Xiao-qing2, LI Li1. Effect of PARP inhibitor combined with Gemcitabine or Docetaxel on the  proliferation of androgen-independent prostate cancer cell line PC3 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(1): 33-36.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd